|
1
|
Babjuk M, Bohle A, Burger M, Capoun O,
Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M,
et al: EAU guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Metts MC, Metts JC, Milito SJ and Thomas
CR Jr: Bladder cancer: A review of diagnosis and management. J Natl
Med Assoc. 92:285–294. 2000.PubMed/NCBI
|
|
4
|
Babjuk M: Trends in bladder cancer
incidence and mortality: Success or Disappointment? Eur Urol.
71:109–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun M and Trinh QD: Diagnosis and staging
of bladder cancer. Hematol Oncol Clin North Am. 29205–218.
(vii)2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vaishampayan U: Systemic therapy of
advanced urothelial cancer. Curr Treat Options Oncol. 10:256–266.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iyer G and Milowsky MI: Fibroblast growth
factor receptor-3 in urothelial tumorigenesis. Urol Oncol.
31:303–311. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Billerey C, Chopin D, Aubriot-Lorton MH,
Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP,
Lefrere-Belda MA, Lahaye JB, Abbou CC, et al: Frequent FGFR3
mutations in papillary non-invasive bladder (pTa) tumors. Am J
Pathol. 158:1955–1959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tomlinson DC, Hurst CD and Knowles MA:
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential
therapeutic target in bladder cancer. Oncogene. 26:5889–5899. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du X, Lin BC, Wang QR, Li H, Ingalla E,
Tien J, Rooney I, Ashkenazi A, Penuel E and Qing J: MMP-1 and
Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of
FGFR3-targeted therapy in patients with bladder cancer. Clin Cancer
Res. 20:6324–6335. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jebar AH, Hurst CD, Tomlinson DC, Johnston
C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are
mutually exclusive genetic events in urothelial cell carcinoma.
Oncogene. 24:5218–5225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang C, Li A, Yang S, Qiao R, Zhu X and
Zhang J: CXCL5 promotes mitomycin C resistance in non-muscle
invasive bladder cancer by activating EMT and NF-κB pathway.
Biochem Biophys Res Commun. 498:862–868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lei ZJ, Wang J, Xiao HL, Guo Y, Wang T, Li
Q, Liu L, Luo X, Fan LL, Lin L, et al: Lysine-specific demethylase
1 promotes the stemness and chemoresistance of Lgr5+ liver cancer
initiating cells by suppressing negative regulators of β-catenin
signaling. Oncogene. 34:32142015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao J: Cancer stem cells and
chemoresistance: The smartest survives the raid. Pharmacol Ther.
160:145–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson MD, O'Connell MJ, Pilcher W and
Reeder JE: Fibroblast growth factor receptor-3 expression in
meningiomas with stimulation of proliferation by the
phosphoinositide 3 kinase-Akt pathway. J Neurosurg. 112:934–939.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan Y, Serra V, Prudkin L, Scaltriti M,
Murli S, Rodriguez O, Guzman M, Sampath D, Nannini M, Xiao Y, et
al: Evaluation and clinical analyses of downstream targets of the
Akt inhibitor GDC-0068. Clin Cancer Res. 19:6976–6986. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan TO, Zhang J, Rodeck U, Pascal JM,
Armen RS, Spring M, Dumitru CD, Myers V, Li X, Cheung JY, et al:
Resistance of Akt kinases to dephosphorylation through
ATP-dependent conformational plasticity. Proc Natl Acad Sci USA.
108:E1120–E1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kajitani N, Glahder J, Wu C, Yu H, Nilsson
K and Schwartz S: hnRNP L controls HPV16 RNA polyadenylation and
splicing in an Akt kinase-dependent manner. Nucleic Acids Res.
45:9654–9678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin J, Sampath D, Nannini MA, Lee BB,
Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, et al:
Targeting activated Akt with GDC-0068, a novel selective Akt
inhibitor that is efficacious in multiple tumor models. Clin Cancer
Res. 19:1760–1772. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clark PE, Agarwal N, Biagioli MC,
Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel
TM, Lele SM, et al: Bladder cancer. J Natl Compr Canc Netw.
11:446–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo G, Sun X, Chen C, Wu S, Huang P, Li Z,
Dean M, Huang Y, Jia W, Zhou Q, et al: Whole-genome and whole-exome
sequencing of bladder cancer identifies frequent alterations in
genes involved in sister chromatid cohesion and segregation. Nat
Genet. 45:1459–1463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guancial EA, Werner L, Bellmunt J, Bamias
A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS,
et al: FGFR3 expression in primary and metastatic urothelial
carcinoma of the bladder. Cancer Med. 3:835–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tian H, Gao Z, Li H, Zhang B, Wang G,
Zhang Q, Pei D and Zheng J: DNA damage response-a double-edged
sword in cancer prevention and cancer therapy. Cancer Lett.
358:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sarkar S, Julicher KP, Burger MS, Della
Valle V, Larsen CJ, Yeager TR, Grossman TB, Nickells RW, Protzel C,
Jarrard DF and Reznikoff CA: Different combinations of
genetic/epigenetic alterations inactivate the p53 and pRb pathways
in invasive human bladder cancers. Cancer Res. 60:3862–3871.
2000.PubMed/NCBI
|
|
29
|
Ren W, Joshi R and Mathew P: Synthetic
Lethality in PTEN-Mutant Prostate Cancer Is Induced by
Combinatorial PI3K/Akt and BCL-XL Inhibition. Mol Cancer Res.
14:1176–1181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li A, Gu Y, Li X, Sun H, Zha H, Xie J,
Zhao J, Huang M, Chen L, Peng Q, et al: S100A6 promotes the
proliferation and migration of cervical cancer cells via the
PI3K/Akt signaling pathway. Oncol Lett. 15:5685–5693.
2018.PubMed/NCBI
|
|
31
|
Wu D, Tao J, Xu B, Qing W, Li P, Lu Q and
Zhang W: Phosphatidylinositol 3-kinase inhibitor LY294002
suppresses proliferation and sensitizes doxorubicin chemotherapy in
bladder cancer cells. Urol Int. 87:105–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeng LP, Hu ZM, Li K and Xia K: miR-222
attenuates cisplatin-induced cell death by targeting the
PPP2R2A/Akt/mTOR Axis in bladder cancer cells. J Cell Mol Med.
20:559–567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pretre V and Wicki A: Inhibition of Akt
and other AGC kinases: A target for clinical cancer therapy? Semin
Cancer Biol. 48:70–77. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galvez-Peralta M, Flatten KS, Loegering
DA, Peterson KL, Schneider PA, Erlichman C and Kaufmann SH:
Context-dependent antagonism between Akt inhibitors and
topoisomerase poisons. Mol Pharmacol. 85:723–734. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rebecca VW, Massaro RR, Fedorenko IV,
Sondak VK, Anderson AR, Kim E, Amaravadi RK, Maria-Engler SS,
Messina JL, Gibney GT, et al: Inhibition of autophagy enhances the
effects of the AKT inhibitor MK-2206 when combined with paclitaxel
and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma
Res. 27:465–478. 2014. View Article : Google Scholar : PubMed/NCBI
|
